Zydus, an innovation driven global healthcare company, today announced that the Adaptive Phase I / II human clinical trials of its plasmid DNA vaccine, ZyCoV-D commenced today with the first human dosing. The Adaptive Phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine. The human dosing of the vaccine marks a key milestone since the launching of the accelerated vaccine development programme for COVID-19 in February 2020.
Speaking on the development, Chairman, Zydus Cadila, Mr. Pankaj R. Patel said, "This is an all important step in our fight against COVID-19. We acknowledge the support of National Biopharma Mission, BIRAC, Department of Biotechnology, Govt. of India and regulatory agencies ICMR and DGCI in the development of ZyCoV-D vaccine candidate. We look forward to the Adaptive Phase I/IIclinical studies and gathering important data on ZyCoV-D in the months ahead."
In the Adaptive Phase I / II clinical trials, Zydus will be enrolling over 1000 subjects across multiple clinical study sites in India. The company has already manufactured clinical GMP batches of the vaccine candidate for the clinical trials.
BR>Zydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) developed at its Vaccine Technology Centre in Ahmedabad, India, has successfully completed the preclinical phase and had received permission from the Drug Controller General of India (DGCI) - Central Drugs Standard Control Organization (CDSCO) to initiate Adaptive Phase I / II human clinical trials in India.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.353.7 as compared to the previous close of Rs. 358.2. The total number of shares traded during the day was 155853 in over 3041 trades.
The stock hit an intraday high of Rs. 361.95 and intraday low of 352.95. The net turnover during the day was Rs. 55691075.